INDSWFTLAB2023-04-012023-06-30 INDSWFTLAB2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member INDSWFTLAB2023-06-30 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532305 INDSWFTLAB NOTLISTED Ind-Swift Laboratories Limited Equity 2023-04-01 2024-03-31 2023-08-09 2023-07-31 INR Lakhs First quarter 16:00:00 19:00:00 2023-08-09 2023-08-09 Not applicable Single segment Pharmaceuticals 2023-04-01 2023-06-30 Unaudited Standalone 2990057000.00 55525000.00 3045582000.00 1462060000.00 13386000.00 61138000.00 382880000.00 203837000.00 138854000.00 472438000.00 2734593000.00 310989000.00 0.00 310989000.00 54336000.00 0.00 54336000.00 -86152000.00 170501000.00 0.00 0.00 0.00 0.00 170501000.00 0.00 170501000.00 0.00 0.00 590869000.00 10 2.89 2.89 0.00 0.00 2.89 2.89 Notes: - 1. The standalone and consolidated financial results have been prepared considering the requirements of Regulation 33 and 52 of the SEBI (LODR) Regulations, 2015, as amended. These results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 9th August, 2023. The above results have been subjected to limited review by the Statutory Auditors of the Company. The reports of the statutory auditors are unqualified. 2. The standalone and consolidated financial statements for the quarter ended June 30, 2023 have been prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015. 3. During the quarter ended June 30, 2023, Company has earned Standalone EBITDA of Rs. 6535.86 Lakhs against EBITDA of Rs. 6015.74 Lakhs for the quarter ended June 30, 2022. Standalone Comprehensive Income for the quarter ended 30th June, 2023 is Rs. 1705.01 Lakhs as compared to Net Comprehensive Income of Rs. 2013.86 for corresponding quarter of previous year. 4. In the Standalone & Consolidated financial results, “Exceptional Items” include: Standalone (Rs. in Lakhs) Quarter Quarter Quarter Year ended Particulars 30.06.2023 31.03.2023 30.06.2022 31.03.2023 Exceptional items 0.00 2664.78 0.00 2664.78 Consolidated (Rs. in Lakhs) Quarter Quarter Quarter Year ended Particulars 30.06.2023 31.03.2023 30.06.2022 31.03.2023 Exceptional items 0.00 2664.78 0.00 2664.78 5. The consolidated financial results include the financial results of the parent company Ind-Swift Laboratories Limited and the financial results of the following subsidiaries/Joint Venture: a) Ind-Swift Laboratories Inc., USA (Subsidiary) b) Fortune (India) Constructions Limited (Subsidiary) c) Indis Healthcare LLP (Joint Venture) d) MJM Remedies Private Limited (Subsidiary-Joint Venture) Ind-Swift Laboratories Limited and its subsidiaries are collectively referred to as ‘the Group’. 6. No adjustment has been made in respect of Deferred Taxes as per IND AS-12, as the same would be provided at the year end. 7. The listed non-convertible debentures of the company aggregating Rs. 424.50 crores as at 31-March-2023 (previous year ended Rs. 424.50 crores) are secured by way of first pari passu charge through mortgage on certain specified immovable & movable assets and the asset cover thereof exceeds hundred percent of the principal amount of the said debentures. 8. During the quarter under review the Company has not issued any Non-Convertible Debt Securities. 9. The previous period figures have been re-grouped and re-classified wherever necessary. 10. The Company is exclusively in the Pharmaceutical Business segment. Other Expenses 472438000.00 0.00 0.00